Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:NTLANYSE:NVSNASDAQ:VYGR On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeNTLAIntellia Therapeutics$8.73-6.2%$10.05$8.30▼$28.23$903.70M1.972.13 million shs3.86 million shsNVSNovartis$110.31-0.7%$107.12$92.35▼$120.92$225.47B0.531.47 million shs2.58 million shsVYGRVoyager Therapeutics$3.72-4.9%$4.59$3.56▼$10.66$205.37M0.99465,879 shs342,035 shsThese 7 Stocks Will Be Magnificent in 2025Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceNTLAIntellia Therapeutics-6.23%-5.01%-28.27%-27.55%-67.46%NVSNovartis-0.75%-1.71%+0.82%+12.16%+15.23%VYGRVoyager Therapeutics-4.86%-4.12%-11.85%-35.64%-59.83%Remove AdsCompare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationNTLAIntellia Therapeutics4.4787 of 5 stars4.31.00.04.71.82.51.3NVSNovartis2.4521 of 5 stars1.93.02.50.03.30.01.9VYGRVoyager Therapeutics4.6336 of 5 stars4.62.00.04.61.31.71.9Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceNTLAIntellia Therapeutics 2.63Moderate Buy$37.56330.19% UpsideNVSNovartis 1.80Reduce$123.3811.84% UpsideVYGRVoyager Therapeutics 3.11Buy$13.97275.44% UpsideCurrent Analyst Ratings BreakdownLatest VYGR, NVS, and NTLA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails3/13/2025VYGRVoyager TherapeuticsCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$14.00 ➝ $12.003/13/2025VYGRVoyager TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$30.00 ➝ $30.003/12/2025VYGRVoyager TherapeuticsWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price TargetOverweight ➝ Overweight$12.00 ➝ $10.003/12/2025VYGRVoyager TherapeuticsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform3/12/2025VYGRVoyager TherapeuticsCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight3/5/2025NTLAIntellia TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$30.003/4/2025NTLAIntellia TherapeuticsTruist FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$90.00 ➝ $50.003/3/2025VYGRVoyager TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$30.00 ➝ $30.002/28/2025NTLAIntellia TherapeuticsBarclaysSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$55.00 ➝ $26.002/28/2025NTLAIntellia TherapeuticsCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetNeutral ➝ Neutral$12.00 ➝ $14.002/28/2025NTLAIntellia TherapeuticsWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$60.00 ➝ $50.00(Data available from 3/26/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookNTLAIntellia Therapeutics$57.88M15.61N/AN/A$11.73 per share0.74NVSNovartis$51.72B4.36$11.00 per share10.03$21.59 per share5.11VYGRVoyager Therapeutics$80.00M2.57$2.64 per share1.41$5.37 per share0.69Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateNTLAIntellia Therapeutics-$481.19M-$5.25N/AN/AN/AN/A-49.34%-40.27%5/8/2025 (Estimated)NVSNovartis$11.94B$5.8818.7612.521.7023.56%37.24%15.85%4/22/2025 (Estimated)VYGRVoyager Therapeutics$132.33M-$1.135.24N/AN/A15.80%8.33%6.15%5/12/2025 (Estimated)Latest VYGR, NVS, and NTLA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails4/22/2025N/ANVSNovartis$2.07N/AN/AN/AN/AN/A3/11/2025Q4 2024VYGRVoyager Therapeutics-$0.35-$0.59-$0.24-$0.59$16.58 million$4.39 million1/31/2025Q4 2024NVSNovartis$1.80$1.98+$0.18$1.41$12.86 billionN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthNTLAIntellia TherapeuticsN/AN/AN/AN/AN/ANVSNovartis$2.512.28%+5.34%42.69%N/AVYGRVoyager TherapeuticsN/AN/AN/AN/AN/ALatest VYGR, NVS, and NTLA DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date2/20/2025NVSNovartis$3.86953/12/20253/12/20253/12/2025(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioNTLAIntellia TherapeuticsN/A6.736.73NVSNovartis0.481.040.84VYGRVoyager TherapeuticsN/A8.458.45Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipNTLAIntellia Therapeutics88.77%NVSNovartis13.12%VYGRVoyager Therapeutics48.03%Insider OwnershipCompanyInsider OwnershipNTLAIntellia Therapeutics3.20%NVSNovartis0.01%VYGRVoyager Therapeutics4.53%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableNTLAIntellia Therapeutics600103.52 million98.59 millionOptionableNVSNovartis75,8832.04 billion2.04 billionOptionableVYGRVoyager Therapeutics10055.21 million52.15 millionOptionableVYGR, NVS, and NTLA HeadlinesRecent News About These CompaniesVoyager Therapeutics (NASDAQ:VYGR) Share Price Passes Below 50 Day Moving Average - Here's What HappenedMarch 25 at 4:30 AM | marketbeat.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Voyager Therapeutics, Inc. - VYGRMarch 19, 2025 | accessnewswire.comHC Wainwright Issues Positive Forecast for VYGR EarningsMarch 18, 2025 | americanbankingnews.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Voyager Therapeutics, Inc. - VYGRMarch 17, 2025 | prnewswire.comQ1 EPS Forecast for Voyager Therapeutics Reduced by AnalystMarch 17, 2025 | americanbankingnews.comHC Wainwright Brokers Boost Earnings Estimates for VYGRMarch 17, 2025 | marketbeat.comWedbush Equities Analysts Reduce Earnings Estimates for VYGRMarch 17, 2025 | marketbeat.comCanaccord Genuity Group Cuts Voyager Therapeutics (NASDAQ:VYGR) Price Target to $12.00March 16, 2025 | americanbankingnews.comCantor Fitzgerald Issues Positive Forecast for VYGR EarningsMarch 16, 2025 | americanbankingnews.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Voyager Therapeutics, Inc. - VYGRMarch 15, 2025 | accessnewswire.comCantor Fitzgerald Issues Positive Outlook for VYGR EarningsMarch 15, 2025 | marketbeat.comCanaccord Genuity Group Issues Pessimistic Forecast for Voyager Therapeutics (NASDAQ:VYGR) Stock PriceMarch 14, 2025 | marketbeat.comVoyager Therapeutics' (VYGR) Buy Rating Reaffirmed at HC WainwrightMarch 14, 2025 | marketbeat.comVoyager Therapeutics price target lowered to $12 from $14 at CanaccordMarch 13, 2025 | markets.businessinsider.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Voyager Therapeutics, Inc. - VYGRMarch 13, 2025 | accessnewswire.comVoyager Therapeutics' (VYGR) Outperform Rating Reaffirmed at WedbushMarch 13, 2025 | marketbeat.comVoyager Therapeutics' (VYGR) Overweight Rating Reiterated at Cantor FitzgeraldMarch 13, 2025 | marketbeat.comA Glimpse Into The Expert Outlook On Voyager Therapeutics Through 4 AnalystsMarch 12, 2025 | benzinga.comVoyager Therapeutics (NASDAQ:VYGR) Releases Earnings Results, Misses Expectations By $0.24 EPSMarch 12, 2025 | marketbeat.comNASA pulls another life-saving maneuver for Voyager from 15 billion miles awayMarch 12, 2025 | earth.comVoyager Therapeutics price target lowered to $10 from $12 at Wells FargoMarch 12, 2025 | markets.businessinsider.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeVYGR, NVS, and NTLA Company DescriptionsIntellia Therapeutics NASDAQ:NTLA$8.73 -0.58 (-6.23%) Closing price 03/25/2025 04:00 PM EasternExtended Trading$8.74 +0.01 (+0.10%) As of 03/25/2025 08:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Intellia Therapeutics, Inc., a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease. It also focusses on programs comprising hemophilia A and hemophilia B; and research of proprietary programs focused on developing engineered cell therapies to treat various cancers and autoimmune diseases. In addition, the company offers tools comprising of Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) system. It has license and collaboration agreement with Regeneron Pharmaceuticals, Inc. to co-develop potential products for the treatment of hemophilia A and hemophilia B; AvenCell Therapeutics, Inc. to develop allogeneic universal CAR-T cell therapies, and co-develop and co-commercialize allogeneic universal CAR-T cell products for an immuno-oncology indication; SparingVision SAS to develop novel genomic medicines utilizing CRISPR/Cas9 technology for the treatment of ocular diseases; Kyverna Therapeutics, Inc. for the development of an allogeneic CD19 CAR-T cell therapy for the treatment of a variety of B cell-mediated autoimmune diseases; and ONK Therapeutics, Ltd. for the development of engineered NK cell therapies to cure patients with cancer. Intellia Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.Novartis NYSE:NVS$110.31 -0.78 (-0.70%) Closing price 03/25/2025 03:58 PM EasternExtended Trading$110.83 +0.52 (+0.47%) As of 03/25/2025 07:27 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran, a therapy to reduce LDL cholesterol; and Dawn Health for the development and commercialization of Ekiva, a digital solution designed for people living with Paroxysmal Nocturnal Hemoglobinuria. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.Voyager Therapeutics NASDAQ:VYGR$3.72 -0.19 (-4.86%) Closing price 03/25/2025 04:00 PM EasternExtended Trading$3.72 0.00 (-0.11%) As of 03/25/2025 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Voyager Therapeutics, Inc., a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial. In addition, the company develops VY-FXN01, which is in preclinical trial to treat friedreich's ataxia; and GBA1 gene replacement to treat parkinson's disease and is in preclinical trial. Further, it provides research program for the treatment of Huntington's disease. The company has collaboration and license agreements with Alexion; AstraZeneca Rare Disease; Novartis Pharma AG; Neurocrine Biosciences, Inc; and Sangamo Therapeutics, Inc. Voyager Therapeutics, Inc. was incorporated in 2013 and is headquartered in Lexington, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas NVIDIA Insiders Sell: This Is What It Means for the Market Oklo’s Stock Price Meltdown Is an Opportunity to Buy Top Dividend Stocks With Over 10 Years of Hikes—and Room to Grow Quantum Gamble? Is IonQ's Stock an Opportunity or a Mirage? Will CrowdStrike's FedRAMP Authorization Move CRWD Stock? Top 3 Insider Stock Buys in March—Are They Still Good in April? Taiwan Semiconductor Attracts Big Money on NVIDIA Chip Growth D-Wave Stock: Is Quantum Blockchain the Next Big Catalyst? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
